Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.

Soliman A, Zamil S, Lotfy A, Ismail E.

Transplant Proc. 2012 Dec;44(10):2936-9. doi: 10.1016/j.transproceed.2012.06.073.

PMID:
23195001
2.

Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.

Riegersperger M, Herkner H, Sunder-Plassmann G.

Trials. 2015 Apr 23;16:182. doi: 10.1186/s13063-015-0692-3.

3.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

4.

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.

N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.

5.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Levey AS, Stevens LA.

N Engl J Med. 2011 Jan 20;364(3):287; author reply 287-9. doi: 10.1056/NEJMc1010845#SA2. No abstract available.

PMID:
21247327
6.

Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.

Wüthrich RP, Kistler AD, Serra AL.

Transplant Proc. 2010 Nov;42(9 Suppl):S44-6. doi: 10.1016/j.transproceed.2010.07.008. Review.

PMID:
21095452
7.

Everolimus in patients with autosomal dominant polycystic kidney disease.

Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.

N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26. Erratum in: N Engl J Med. 2010 Sep 16;363(12):1190. N Engl J Med. 2010 Nov 11;363(20):1977.

8.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

9.

Sirolimus therapy to halt the progression of ADPKD.

Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G.

J Am Soc Nephrol. 2010 Jun;21(6):1031-40. doi: 10.1681/ASN.2009121302. Epub 2010 May 13.

10.

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.

Nephrol Dial Transplant. 2006 Mar;21(3):598-604. Epub 2005 Oct 12.

PMID:
16221708
11.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Braun WE.

N Engl J Med. 2011 Jan 20;364(3):287; author reply 287-8. doi: 10.1056/NEJMc1010845#SA3. No abstract available.

PMID:
21247326
12.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Grantham JJ, Bennett WM, Perrone RD.

N Engl J Med. 2011 Jan 20;364(3):286-7; author reply 287-9. doi: 10.1056/NEJMc1010845#SA1. No abstract available.

PMID:
21247328
13.

Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study.

Soliman AR, Ismail E, Zamil S, Lotfy A.

Transplant Proc. 2009 Nov;41(9):3639-41. doi: 10.1016/j.transproceed.2009.05.032.

PMID:
19917358
14.

Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.

Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR.

Clin J Am Soc Nephrol. 2014 May;9(5):881-8. doi: 10.2215/CJN.02650313. Epub 2014 Apr 10.

15.

Improvement of coronary flow velocity reserve with telmisartan in patients with autosomal-dominant polycystic kidney disease.

Alisir S, Turkmen K, Alpay N, Elitok A, Oflaz H, Uslu B, Cimen A, Kasikcioglu E, Tufan F, Ecder T.

South Med J. 2010 May;103(5):409-13. doi: 10.1097/SMJ.0b013e3181d80cae.

PMID:
20375940
16.
17.

Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.

Ponticelli C, Locatelli F.

Nephrol Dial Transplant. 2010 Dec;25(12):3809-12. doi: 10.1093/ndt/gfq527. Epub 2010 Aug 26. No abstract available.

PMID:
20798121
18.

Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.

Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP.

Nephrol Dial Transplant. 2009 Nov;24(11):3334-42. doi: 10.1093/ndt/gfp280. Epub 2009 Jun 13.

PMID:
19525519
19.

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.

Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L.

Nephrol Dial Transplant. 2012 Sep;27(9):3560-7. doi: 10.1093/ndt/gfs264. Epub 2012 Jul 10.

PMID:
22785114
20.

Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.

Xue C, Dai B, Mei C.

Nephron Clin Pract. 2013;124(1-2):10-6. doi: 10.1159/000354398. Epub 2013 Sep 6. Review.

PMID:
24022660

Supplemental Content

Support Center